NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$31.89
1.03 (3.32%)
▲
5d:
+8.64%
30d:
+15.07%
90d:
+52.56%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $31.89, which is considered extended relative to its 30-day fair value range of $26.76 to $30.23.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $24.91, while resistance sits at $32.97. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.00 (+159.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $24.91, while resistance sits at $32.97. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.00 (+159.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$26.76 -
$30.23
Company Quality Score
61/100
(BUY)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range (+5.5% above its trading range)
- BULLISH: Options cheap (IV 16th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 159.2% below Wall St target ($80.00)
Trading Range Analysis
30-Day Trading Range
$26.76 -
$30.23
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.30
(16.6%)
Support & Resistance Levels
Support Level
$24.91
Resistance Level
$32.97
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.52
Wall Street Target
$80.00
(+159.2%)
Share & Embed Analysis
Last updated: June 24, 2026 10:48 AM ET
Data refreshes hourly during market hours. Next update: 11:48 AM
Data refreshes hourly during market hours. Next update: 11:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
